FDA accepts Avanir IND for AVP-923 to treat agitation in patients with AD

Jun 11 2012NewsGuard 100/100 Score

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD). The company plans to initiate a Phase II study evaluating AVP-923 during the third calendar quarter of 2012.

"This marks the fourth IND for the AVP-923 program, reflecting our belief that the unique dual sigma-1 and NMDA receptor pharmacology has significant potential," said Joao Siffert, MD, senior vice president of R&D at Avanir Pharmaceuticals. "With no approved treatments for agitation in patients with Alzheimer's disease, this remains an area of tremendous unmet medical need. We look forward to initiating our clinical research program later this year."

SOURCE Avanir Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Updated Food Compass 2.0 improves food health ratings using new diet data
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group
Ultra-processed food linked to weight gain and lower well-being in adolescents
High levels of microplastics found in prostate tumors, possibly linked to take-out food
Limiting fast-food outlets can reduce childhood overweight and obesity
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty
Frequent ultra-processed food consumption raises mortality risks, especially in women
Calcium channel blockers show potential to restore cerebral blood flow in Alzheimer's disease

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
The molecular underpinnings by which traumatic brain injury increases Alzheimer's disease risk